PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
PMV Pharmaceuticals, Inc. (PMVP)
Company Research
Source: GlobeNewswire
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women’s Cancer Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 2024, providing expected cash runway to end of 2026 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “Dosing the first patient in the registrational, tumor-agnostic Phase 2 portion of the PYNNACLE trial was an important milestone for PMV. Our team has worked d
Show less
Read more
Impact Snapshot
Event Time:
PMVP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PMVP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PMVP alerts
High impacting PMV Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PMVP
News
- PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) was upgraded by analysts at CLSA to a "strong-buy" rating.MarketBeat
- PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
PMVP
Earnings
- 5/9/24 - Beat
PMVP
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/24/24 - Form ARS
- PMVP's page on the SEC website